Science Daily: Pharmacology News

MARCH 10, 2025

The research shows that by exploiting a cellular enzyme, the virus can produce behavioral symptoms. The finding emphasizes the need for prevention and treatment of a virus carried by billions of people worldwide. A study finds that herpes infection through the nose can lead to anxiety, motor impairment and cognitive issues.

Virus 288

Virus Treatment Research 288

Drug Discovery Today

JANUARY 29, 2020

This new development from a collaborative team of international scientists shows promise for the treatment of herpes simplex (cold sore virus), respiratory syncytial virus, hepatitis C, HIV, and Zika virus to name a few.

Virus 170

Virus International Treatment 170

Science Daily: Pharmacology News

AUGUST 9, 2023

The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.

Licensing 172

Licensing Licensing Treatment Virus 172

Science Daily: Pharmacology News

OCTOBER 18, 2023

Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months.

Therapies 225

Therapies Immune Response Research Virus 225

Drug Discovery Today

DECEMBER 9, 2019

A team of molecular and structural biologists from Nanyang Technological University, Singapore (NTU Singapore) have found a potential new route to disabling respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) after elucidating the structure of one of its key components.

Virus 100

Virus Treatment 100

SCIENMAG: Medicine & Health

JUNE 20, 2023

EDMONTON — Combining a cancer-targeting virus with radiation to treat brain cancer in mice was more effective than either therapy on its own according to University of Alberta research, providing hope for new treatments that combine immunotherapy with traditional surgery, chemotherapy or radiation.

Virus 83

Virus Therapies Treatment Research 83

SCIENMAG: Medicine & Health

AUGUST 16, 2023

(Philadelphia, PA) – A single injection of a novel CRISPR gene-editing treatment safely and efficiently removes SIV – a virus related to the AIDS-causing agent HIV – from the genomes of non-human primates, scientists at the Lewis Katz School of Medicine at Temple University now report.

Virus 77

Virus Treatment Engineering 77

SCIENMAG: Medicine & Health

AUGUST 8, 2023

Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption. However, the mechanisms enabling this post-treatment control have not been fully elucidated.

Virus 89

Virus Hospitals Treatment 89

ProRelix Research

SEPTEMBER 7, 2023

Autoimmune disorders comprise several diseases in which the immune system mistakenly attacks and destroys the body’s own healthy cells instead of destroying bacteria and viruses to keep the body healthy. […] The post Autoimmune disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.

Clinical Trials 105

Clinical Trials Trials Treatment Virus 105

SCIENMAG: Medicine & Health

MARCH 28, 2024

DETROIT – A groundbreaking study published in the journal iScience presents crucial insights into the ocular effects of Zika virus infection during pregnancy and offers promising avenues for therapeutic intervention.

Virus 67

Virus Treatment Research 67

DrugBank

MARCH 12, 2025

  The Expanding Role of mRNA in Cancer Therapy One of the most exciting applications of mRNA therapeutics lies in cancer treatment, where leveraging the immune system to target tumors offers a novel approach. These findings underscore the potential of mRNA to redefine cancer treatment by offering precise, patient-specific therapies.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

Drug Discovery Today

MARCH 1, 2022

The study’s authors say that this may make complete clearance of the virus from the body of an infected person, by their own antibodies, or by therapeutic antibody treatments, much more difficult.

Virus 100

Virus Research International Treatment 100

Chemical Biology and Drug Design

APRIL 18, 2023

Current chemotherapeutics are obsolete, and one of the primary reasons for treatment cessation is their poor safety and effectiveness. Due to the aforementioned challenges, researchers are now focusing on discovering alternative novel safe, and economically reachable therapies for the treatment of trypanosomiasis.

Treatment 100

Treatment Disease Virus Therapies 100

Drug Target Review

OCTOBER 25, 2023

Their findings may result in new treatments for reproductive conditions. He stated that this could inform new treatments for reproductive conditions like recurrent pregnancy loss and preeclampsia. A human foetus contains genetic material from both parents, which makes it partly foreign to the pregnant person’s body.

Treatment 105

Treatment Virus Research Science 105

Broad Institute

JUNE 18, 2024

Simple test for flu could improve diagnosis and surveillance By Allessandra DiCorato June 18, 2024 Breadcrumb Home Simple test for flu could improve diagnosis and surveillance A low-cost CRISPR-based paper strip test distinguishes between influenza types and can be reprogrammed to recognize different viruses including the H5N1 bird flu virus.

Virus 144

Virus RNA Laboratories Medical Schools 144

Broad Institute

JULY 11, 2024

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus.

Treatment 72

Treatment Immune Response Drugs Virus 72

Drug Discovery Today

FEBRUARY 16, 2021

Celltrion has constructed a COVID-19 antibody portfolio and clinical development platform to help combat the spread of the virus mutations CT-P59 demonstrated neutralising capability against key emerging mutations, including the UK variant in addition to six variant genome mutations of SARS-CoV-2.

Clinical Development 113

Clinical Development Virus Treatment 113

Covalent Modifiers

MARCH 13, 2024

We hypothesized that the covalent hepatitis C virus protease inhibitor boceprevir (BPV) could serve as the basis for orally bioavailable drugs that inhibit SARS-CoV-2 Mpro more efficiently than existing drugs. Second-generation oral drugs that retain function against these mutants are thus urgently needed.

Pharmacokinetics 162

Pharmacokinetics Virus Treatment Drugs 162

The Pharma Data

AUGUST 6, 2020

People with symptomless Covid-19 can carry as much of the virus as those with symptoms, a South Korean study has suggested. But the researchers weren’t able to say how much these people actually passed the virus on. In theory, having the same amount of virus in your nose and throat means you have just as much to pass on.

Virus 52

Virus Disease Treatment Research 52

The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52

Virus Small Molecule Protein Production Research 52

The Pharma Data

AUGUST 13, 2020

A further 21% of 1,030 doctors who had since recovered from the virus reported chronic fatigue, while 11% said they had no concentration difficulties. 26% of doctors who had participated in the study believed they had COVID-19. We cannot afford more failures of quality and supply in personal protective equipment. Conor Kavanagh.

Virus 52

Virus Doctors Government Treatment 52

SCIENMAG: Medicine & Health

AUGUST 2, 2023

Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dosing, safety and effectiveness of a drug formulation designed for treating children with human immunodeficiency virus (HIV).

Treatment 63

Treatment Virus Drugs Research 63

The Pharma Data

APRIL 15, 2022

Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. The top protein neutralized the virus with similar or greater potency than antibody treatments with Emergency Use Authorization status from the U.S.

Treatment 52

Treatment Virus Laboratories Engineering 52

The Pharma Data

NOVEMBER 10, 2020

Antibody Treatment Approved for Emergency Use Against Early COVID-19. 10, 2020 — Eli Lilly’s experimental antibody treatment for COVID-19 was given emergency approval by the U.S. Instead, the treatment should be given as soon as possible after a positive test and within 10 days of developing symptoms. Professional.

Treatment 52

Treatment Government Hospitals FDA 52

The Pharma Data

NOVEMBER 11, 2020

Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. In addition, SLV213 potentially has broad antiviral activity against coronaviruses, Ebola viruses, and paramyxoviruses, including Nipah virus.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

JANUARY 21, 2021

Cabenuva reduces the treatment dosing days from 365 days to 12 days per year. Before beginning treatment with Cabenuva, patients took oral doses of both cabotegravir and rilpivirine for about a month to determine if the patients could tolerate it. The approval was built on the Phase III ATLAS and FLAIR trials. Most Read Today.

FDA Approval 52

FDA Approval Treatment FDA Clinical Trials 52

The Pharma Data

AUGUST 28, 2020

Celltrion Group has announced that the Korean Ministry of Food and Drug Safety has approved the company’s Investigational New Drug application for a Phase 1 trial for their coronavirus antiviral antibody treatment candidate. Conor Kavanagh.

Trials 52

Trials Treatment Clinical Trials Pharmacokinetics 52

ASPET

JUNE 12, 2024

We developed self-complimentary adeno-associated virus vectors (scAAV9) expressing two splice variants of human GNAO1 Gα o isoforms 1 (G o A, GNAO1.1 ) and 2 (G o B, GNAO1.2 ). GNAO1 overexpression did not increase seizure susceptibility, a potential side-effect of GNAO1 vector treatment. or scAAV9- GNAO1.2 or scAAV9- GNAO1.2

Therapies 100

Therapies Virus Treatment 100

Broad Institute

MAY 16, 2024

Gene therapy could potentially treat a range of severe genetic brain disorders, which currently have no cures and few treatment options. Sonia Vallabh and Eric Minikel , two researchers at the Broad who are developing treatments for prion disease, are excited by the potential of the AAVs to deliver brain therapies in humans.

Therapies 137

Therapies FDA Approval Engineering Disease 137

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Therapies 119

Therapies FDA FDA Approval Treatment 119

SCIENMAG: Medicine & Health

JUNE 21, 2023

In an earlier clinical trial, in which the Bochum researchers were also involved, patients with chronic hepatitis E virus (HEV) infection were treated with the drug sofosbuvir, which was actually developed for the treatment of hepatitis C. […] Credit: © RUB, Marquard Which viral variants circulate in the blood?

Therapies 72

Therapies Clinical Trials Virus Trials 72

The Pharma Data

OCTOBER 22, 2020

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19.

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

JANUARY 6, 2021

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ The published study results showed that OYA1 was “highly effective” in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID.

Virus 40

Virus Clinical Trials Government Laboratories 40

The Pharma Data

AUGUST 27, 2020

The company has already tested the treatment on 10 adults between the ages of 56-70, and 10 over 71. These antibodies were higher than those seen in people who had recovered from the virus. Each patient was given two 100 microgram doses of the vaccine 28 days apart. million.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture.

Trials 69

Trials Virus RNA Research Laboratories 69

Drug Target Review

AUGUST 25, 2023

What makes RRx-001 a first-in-class hypoxia-activated therapeutic, and how does its dual mechanism of action differ from traditional cancer treatments? Most, if not all, traditional cancer treatments are single minded. The virus carries a transforming growth factor- beta (TGF-β), which it expresses at high levels.

Small Molecule 98

Small Molecule Virus International Clinical Trials 98

The Pharma Data

DECEMBER 20, 2020

20 , 2020 /PRNewswire/ — The broad spectrum antiviral therapeutic, ‘hzVSF-v13(humanized Virus Suppressing Factor)’ being developed by ImmuneMed , is on track to progress as a treatment for the COVID-19 pneumonia patients. CHUNCHEON, South Korea , Dec. Media Contact.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40